Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics reported a 17% year-over-year increase in the sale of nanochannel array flowcells in 2Q25, reaching 7,233 units compared to 6,165 in 2Q24, and an additional 7% growth in sales during 3Q25. The company achieved an 11% year-over-year growth in combined revenue from consumables, software, and remaining services in 2Q25, with consumables and software alone rising by 16%. Furthermore, Bionano's expectations for new optical genome mapping (OGM) installations in FY2025 have increased to a range of 20-25 units, reflecting robust momentum in both established and expanding international markets.

Bears say

Bionano Genomics faces significant risks that could hinder its financial performance, including lower than projected market uptake and utilization of its products and systems. Additionally, the company's reliance on securing further capital to fund operations raises concerns about its financial stability, alongside the inherent dilution risk associated with such capital raises. Furthermore, based on comparative valuation metrics, the projected financial outlook suggests a price objective of approximately $11, which implies potential challenges in sustaining investor confidence given these adverse factors.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.